ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Fosun Pharma and GlaxoSmithKline side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Fosun PharmaGlaxoSmithKline
studies on the registry2024,198
open to participants now86135
phase 3 studies under way2376
reach primary completion within a year3966
programswith a study of their own in two years49+18 named only88+17 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseFosun PharmaGlaxoSmithKline
Phase 1

Fosun Pharma: 27 of its 49 programs at phase 1

  1. HLX319phase 1
  2. Anti-PD-1/IL-2 Fusion Protein TEV-56278phase 1
  3. Cetuximabphase 1
  4. FXS0260phase 1
  5. FXS0683phase 1

and 22 more — sign in to see them all

55%

GlaxoSmithKline: 19 of its 88 programs at phase 1

  1. Pn-MAPS30plusphase 1
  2. GSK4771261phase 1
  3. Antibody-drug Conjugate GSK5533524phase 1
  4. ganfeborolephase 1
  5. GSK4425689Aphase 1

and 14 more — sign in to see them all

22%
Phase 2

Fosun Pharma: 9 of its 49 programs at phase 2

  1. BRAF V600E Inhibitor HLX208phase 2
  2. Bcl-2 Inhibitor LOXO-338phase 2
  3. FKC289phase 2
  4. FXR0906phase 2
  5. XH-S003 Capsulephase 2

and 4 more — sign in to see them all

18%

GlaxoSmithKline: 36 of its 88 programs at phase 2

  1. dezecapavirphase 2
  2. nelistotugphase 2
  3. GSK3862995Bphase 2
  4. VH4524184phase 2
  5. nirogacestatphase 2

and 31 more — sign in to see them all

41%
Phase 3

Fosun Pharma: 13 of its 49 programs at phase 3

  1. Anti-PD-L1 Antibody-drug Conjugate HLX43phase 3
  2. serplulimabphase 3
  3. pimurutamabphase 3
  4. luvometinibphase 3
  5. dulpatatugphase 3

and 8 more — sign in to see them all

27%

GlaxoSmithKline: 23 of its 88 programs at phase 3

  1. belantamab mafodotinphase 3
  2. felcorekibartphase 3
  3. risvutatug rezetecanphase 3
  4. velzatinibphase 3
  5. efimosfermin alfaphase 3

and 18 more — sign in to see them all

26%
Approved, new studies00%

GlaxoSmithKline: 10 of its 88 programs at approved, new studies

  1. dostarlimabapproved, new study
  2. cabotegravirapproved, new study
  3. depemokimabapproved, new study
  4. belimumabapproved, new study
  5. niraparibapproved, new study

and 5 more — sign in to see them all

11%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Fosun Pharma21 readouts · 3 phase 3

Fosun Pharma, Nov ’26: 2 programs whose next study reaches primary completion

  1. Anti-PD-L1 Antibody-drug Conjugate HLX43phase 3 · Nov 22 · NCT06839066
  2. FKC876early phase 1 · Nov 30 · NCT07606937

Fosun Pharma, Dec ’26: 2 programs whose next study reaches primary completion

  1. HLX13phase 3 · Dec 0 · NCT07176650
  2. Bcl-2 Inhibitor LOXO-338phase 2 · Dec 1 · NCT06858618

Fosun Pharma, Jan ’27: 1 program whose next study reaches primary completion

  1. HLX29phase 1 · Jan 31 · NCT07776132

Fosun Pharma, Feb ’27: 1 program whose next study reaches primary completion

  1. FXS5626phase 3 · Feb 28 · NCT07552012

Fosun Pharma, Mar ’27: 2 programs whose next study reaches primary completion

  1. HLX48phase 1 · Mar 0 · NCT07473726
  2. HLX37phase 3 · Mar 30 · NCT07274813

Fosun Pharma, Apr ’27: 5 programs whose next study reaches primary completion, 2 in phase 3

  1. HLX17phase 3 · Apr 9 · NCT06847334
  2. HLX319phase 1 · Apr 23 · NCT07601620
  3. FXS887phase 1 · Apr 28 · NCT07345637
  4. FXS6837phase 3 · Apr 29 · NCT07949799
  5. luvometinibphase 3 · Apr 30 · NCT07004075

Fosun Pharma, May ’27: 1 program whose next study reaches primary completion

  1. HLX15phase 3 · May 25 · NCT07477587

Fosun Pharma, Jun ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. dulpatatugphase 3 · Jun 1 · NCT06532006
  2. HLX3902phase 1 · Jun 29 · NCT07533708
  3. Cetuximabphase 1 · Jun 30 · NCT07543471

Fosun Pharma, Jul ’27: 1 program whose next study reaches primary completion

  1. pimurutamabphase 3 · Jul 28 · NCT07358585

Fosun Pharma, Aug ’27: 1 program whose next study reaches primary completion

  1. HLX18phase 1 · Aug 12 · NCT07518043

Fosun Pharma, Sep ’27: 2 programs whose next study reaches primary completion

  1. HLX109phase 1 · Sep 20 · NCT07935941
  2. FXR0906phase 2 · Sep 24 · NCT07766759
·
GlaxoSmithKline40 readouts · 8 phase 3

GlaxoSmithKline, Nov ’26: 3 programs whose next study reaches primary completion, 2 in phase 3

  1. dostarlimabapproved, new study · Nov 23 · NCT06567782
  2. Pentetic Acidphase 3 · Nov 23 · NCT07596199
  3. niraparibapproved, new study · Nov 26 · NCT03981796

GlaxoSmithKline, Dec ’26: 6 programs whose next study reaches primary completion, 2 in phase 3

  1. Investigational mRNA Seasonal Flu/COVID-19 Combination (Flu/COVm) Vaccinephase 1 · Dec 3 · NCT07464314
  2. momelotinibphase 3 · Dec 11 · NCT03441113
  3. GSK3862995Bphase 2 · Dec 16 · NCT06154837
  4. HFA-152aphase 3 · Dec 28 · NCT07645248
  5. norfluranephase 3 · Dec 28 · NCT07645248

and 1 more — sign in to see them all

GlaxoSmithKline, Jan ’27: 4 programs whose next study reaches primary completion

  1. Adjuvanted RSVPreF3 vaccinephase 2 · Jan 12 · NCT07092865
  2. velzatinibphase 3 · Jan 12 · NCT07862114
  3. SOC INSTI-based ARTphase 1 · Jan 22 · NCT07053384
  4. VH3810109phase 2 · Jan 22 · NCT07053384

GlaxoSmithKline, Feb ’27: 2 programs whose next study reaches primary completion

  1. dezecapavirphase 2 · Feb 18 · NCT07934719
  2. Pn-MAPS30plusphase 1 · Feb 22 · NCT07406334

GlaxoSmithKline, Mar ’27: 6 programs whose next study reaches primary completion, 1 in phase 3

  1. depemokimabapproved, new study · Mar 1 · NCT07671001
  2. CAB ULAphase 3 · Mar 8 · NCT06786520
  3. cabotegravirapproved, new study · Mar 8 · NCT06786520
  4. camlipixantphase 3 · Mar 9 · NCT07519395
  5. ozureprubartphase 2 · Mar 16 · NCT07220811

and 1 more — sign in to see them all

GlaxoSmithKline, Apr ’27: 2 programs whose next study reaches primary completion

  1. felcorekibartphase 3 · Apr 13 · NCT07712393
  2. as01ephase 2 · Apr 23 · NCT07036159

GlaxoSmithKline, May ’27: 5 programs whose next study reaches primary completion

  1. Candidate UTI vaccine HTD formulation 2phase 2 · May 3 · NCT06702449
  2. Candidate UTI vaccine low dose formulation 1phase 2 · May 3 · NCT06702449
  3. VH4770359phase 1 · May 5 · NCT07525544
  4. gepotidacinphase 3 · May 17 · NCT07645235
  5. GSK4771261phase 1 · May 20 · NCT07600450

GlaxoSmithKline, Jun ’27: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. Bevacizumabphase 2 · Jun 21 · NCT06796907
  2. belimumabapproved, new study · Jun 29 · NCT06411249
  3. Low dose Strep A Alumphase 1 · Jun 29 · NCT07085702
  4. Low dose Strep A AS37phase 1 · Jun 29 · NCT07085702

GlaxoSmithKline, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. mRNA Seasonal Flu vaccinephase 3 · Jul 9 · NCT07851246

GlaxoSmithKline, Aug ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. belantamabphase 2 · Aug 5 · NCT07742527
  2. shingrixapproved, new study · Aug 23 · NCT05371080

GlaxoSmithKline, Sep ’27: 1 program whose next study reaches primary completion

  1. mocertatug rezetecanphase 3 · Sep 22 · NCT06431594

GlaxoSmithKline, Oct ’27: 4 programs whose next study reaches primary completion

  1. GSK3772701phase 2 · Oct 8 · NCT07545681
  2. efimosfermin alfaphase 3 · Oct 13 · NCT07358546
  3. Anti-PSMA/Anti-CD3 T-cell Engager GSK5458514phase 2 · Oct 26 · NCT06990880
  4. VH4524184phase 2 · Oct 28 · NCT07202546
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 23, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Fosun Pharma

New programs 5

  • HLX49phase 1 · first study · Nov 12
  • HLX105phase 1 · first study · Nov 4
  • FXS0260phase 1 · first study · Oct 25
  • HLX109phase 1 · first study · Oct 18
  • FXS4640phase 1 · first study · Sep 23

Reached a new phase 3

  • FXR0906phase 2 · Oct 13
  • HLX37phase 3 · Oct 4 · Carcinoma, Non-Small-Cell Lung
  • FXS5626phase 3 · Sep 17 · Uveitis

Study stopped 0

None

Primary completion later 1

GlaxoSmithKline

New programs 4

Reached a new phase 0

None

Study stopped 2

  • camlipixantphase 3 · terminated Nov 20“The study has been terminated due to the decision to cease further development of camlipixant in refractory…” · NCT05600777
  • camlipixantphase 3 · terminated Nov 20“The study has been withdrawn terminated due to the decision to cease further development of camlipixant in …” · NCT07650084

Primary completion later 10

Where they overlap

Conditions where at least two of them have programs: 17 in all. A program counts in each condition its studies name most.

ConditionFosun PharmaGlaxoSmithKline
Carcinoma, Non-Small-Cell Lungboth · compare here

Fosun Pharma in Carcinoma, Non-Small-Cell Lung: 11 programs

  1. Anti-PD-L1 Antibody-drug Conjugate HLX43phase 3
  2. serplulimabphase 3
  3. pimurutamabphase 3
  4. HLX17phase 3
  5. HLX37phase 3

and 6 more — sign in to see them all

Their studies: Fosun Pharma’s studies of Carcinoma, Non-Small-Cell Lung in search

GlaxoSmithKline in Carcinoma, Non-Small-Cell Lung: 8 programs

  1. risvutatug rezetecanphase 3
  2. momelotinibphase 3
  3. neladalkibphase 3
  4. feladilimabphase 3
  5. nelistotugphase 2

and 3 more — sign in to see them all

Their studies: GlaxoSmithKline’s studies of Carcinoma, Non-Small-Cell Lung in search

Neoplasmsboth · compare here

Fosun Pharma in Neoplasms: 5 programs

  1. anlotinibphase 2
  2. Folfox protocolphase 2
  3. Cetuximabphase 1
  4. HLX05phase 1
  5. ifebemtinibno phase

Their studies: Fosun Pharma’s studies of Neoplasms in search

Breast Neoplasmsboth · compare here

Fosun Pharma in Breast Neoplasms: 6 programs

  1. Anti-PD-L1 Antibody-drug Conjugate HLX43phase 3
  2. dulpatatugphase 3
  3. HLX87phase 3
  4. hx22phase 3
  5. HLX319phase 1

and 1 more — sign in to see them all

Their studies: Fosun Pharma’s studies of Breast Neoplasms in search

GlaxoSmithKline in Breast Neoplasms: 3 programs

  1. nirogacestatphase 2
  2. Bevacizumabphase 2
  3. niraparibapproved, new study

Their studies: GlaxoSmithKline’s studies of Breast Neoplasms in search

Colorectal Neoplasmsboth · compare here

Fosun Pharma in Colorectal Neoplasms: 5 programs

  1. serplulimabphase 3
  2. BRAF V600E Inhibitor HLX208phase 2
  3. Folfox protocolphase 2
  4. XS-03phase 2
  5. Cetuximabphase 1

Their studies: Fosun Pharma’s studies of Colorectal Neoplasms in search

Multiple Myelomaboth · compare here

Fosun Pharma in Multiple Myeloma: 2 programs

  1. HLX15phase 3
  2. hyaluronidase (human recombinant)phase 1

Their studies: Fosun Pharma’s studies of Multiple Myeloma in search

GlaxoSmithKline in Multiple Myeloma: 5 programs

  1. belantamab mafodotinphase 3
  2. feladilimabphase 3
  3. nirogacestatphase 2
  4. belantamabphase 2
  5. isatuximabphase 2

Their studies: GlaxoSmithKline’s studies of Multiple Myeloma in search

Ovarian Neoplasmsboth · compare here

Fosun Pharma in Ovarian Neoplasms: 1 program

  1. ifebemtinibno phase

Their studies: Fosun Pharma’s studies of Ovarian Neoplasms in search

GlaxoSmithKline in Ovarian Neoplasms: 6 programs

  1. mocertatug rezetecanphase 3
  2. nirogacestatphase 2
  3. Bevacizumabphase 2
  4. ivonescimabphase 2
  5. dostarlimabapproved, new study

and 1 more — sign in to see them all

Their studies: GlaxoSmithKline’s studies of Ovarian Neoplasms in search

Small Cell Lung Carcinomaboth · compare here

Fosun Pharma in Small Cell Lung Carcinoma: 3 programs

  1. serplulimabphase 3
  2. anlotinibphase 2
  3. ifebemtinibno phase

Their studies: Fosun Pharma’s studies of Small Cell Lung Carcinoma in search

GlaxoSmithKline in Small Cell Lung Carcinoma: 2 programs

  1. risvutatug rezetecanphase 3
  2. ivonescimabphase 2

Their studies: GlaxoSmithKline’s studies of Small Cell Lung Carcinoma in search

Urinary Tract Infectionsboth · compare here

Fosun Pharma in Urinary Tract Infections: 1 program

  1. nacubactamno phase

Their studies: Fosun Pharma’s studies of Urinary Tract Infections in search

Pulmonary Disease, Chronic Obstructiveboth · compare here

Fosun Pharma in Pulmonary Disease, Chronic Obstructive: 1 program

  1. fxs7553 doseno phase

Their studies: Fosun Pharma’s studies of Pulmonary Disease, Chronic Obstructive in search

GlaxoSmithKline in Pulmonary Disease, Chronic Obstructive: 3 programs

  1. felcorekibartphase 3
  2. GSK3862995Bphase 2
  3. depemokimabapproved, new study

Their studies: GlaxoSmithKline’s studies of Pulmonary Disease, Chronic Obstructive in search

Squamous Cell Carcinoma of Head and Neckboth · compare here

Fosun Pharma in Squamous Cell Carcinoma of Head and Neck: 2 programs

  1. pimurutamabphase 3
  2. Cetuximabphase 1

Their studies: Fosun Pharma’s studies of Squamous Cell Carcinoma of Head and Neck in search

GlaxoSmithKline in Squamous Cell Carcinoma of Head and Neck: 2 programs

  1. feladilimabphase 3
  2. nelistotugphase 2

Their studies: GlaxoSmithKline’s studies of Squamous Cell Carcinoma of Head and Neck in search

Endometrial Neoplasmsboth · compare here

Fosun Pharma in Endometrial Neoplasms: 1 program

  1. anlotinibphase 2

Their studies: Fosun Pharma’s studies of Endometrial Neoplasms in search

GlaxoSmithKline in Endometrial Neoplasms: 2 programs

  1. mocertatug rezetecanphase 3
  2. dostarlimabapproved, new study

Their studies: GlaxoSmithKline’s studies of Endometrial Neoplasms in search

Neoplasm Metastasisboth · compare here

Fosun Pharma in Neoplasm Metastasis: 2 programs

  1. serplulimabphase 3
  2. luvometinibphase 3

Their studies: Fosun Pharma’s studies of Neoplasm Metastasis in search

GlaxoSmithKline in Neoplasm Metastasis: 1 program

  1. neladalkibphase 3

Their studies: GlaxoSmithKline’s studies of Neoplasm Metastasis in search

Alzheimer Diseaseboth · compare here

Fosun Pharma in Alzheimer Disease: 1 program

  1. GV-971no phase

Their studies: Fosun Pharma’s studies of Alzheimer Disease in search

GlaxoSmithKline in Alzheimer Disease: 1 program

  1. nivisnebartphase 2

Their studies: GlaxoSmithKline’s studies of Alzheimer Disease in search

Carcinoma, Hepatocellularboth · compare here

Fosun Pharma in Carcinoma, Hepatocellular: 1 program

  1. HLX13phase 3

Their studies: Fosun Pharma’s studies of Carcinoma, Hepatocellular in search

GlaxoSmithKline in Carcinoma, Hepatocellular: 1 program

  1. Bevacizumabphase 2

Their studies: GlaxoSmithKline’s studies of Carcinoma, Hepatocellular in search

Glomerulonephritis, Membranousboth · compare here

Fosun Pharma in Glomerulonephritis, Membranous: 1 program

  1. FKC289phase 2

Their studies: Fosun Pharma’s studies of Glomerulonephritis, Membranous in search

GlaxoSmithKline in Glomerulonephritis, Membranous: 1 program

  1. belimumabapproved, new study

Their studies: GlaxoSmithKline’s studies of Glomerulonephritis, Membranous in search

Head and Neck Neoplasmsboth · compare here

Fosun Pharma in Head and Neck Neoplasms: 1 program

  1. Cetuximabphase 1

Their studies: Fosun Pharma’s studies of Head and Neck Neoplasms in search

GlaxoSmithKline in Head and Neck Neoplasms: 1 program

  1. feladilimabphase 3

Their studies: GlaxoSmithKline’s studies of Head and Neck Neoplasms in search

Triple Negative Breast Neoplasmsboth · compare here

Fosun Pharma in Triple Negative Breast Neoplasms: 1 program

  1. Anti-PD-L1 Antibody-drug Conjugate HLX43phase 3

Their studies: Fosun Pharma’s studies of Triple Negative Breast Neoplasms in search

GlaxoSmithKline in Triple Negative Breast Neoplasms: 1 program

  1. ivonescimabphase 2

Their studies: GlaxoSmithKline’s studies of Triple Negative Breast Neoplasms in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: Fosun Pharma 25 of 49 · GlaxoSmithKline 65 of 88 programs (23 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Fosun Pharma: 18, GlaxoSmithKline: 17).